N-(piperidin-1-yl)-5-(4-iodophe-nyl)-1-(2,4-dichlorophenyl)-4-methyl-1 H-pyrazole-3-carboxamide (AM251), and R-( + )-(2, 3-dihydro-5-methyl-3-[(4morpholinyl)methyl]pyrol[1,2,3-de]-1,4-benzoxazin-6-yl)(1-naphthalenyl) methanone mono-methanesulfonate (WIN55212-2), and (5Z,8Z,11Z,14Z)-5,8,11, 14-eicosatetraenyl-methyl ester phosphonofluoridic acid (MAFP) were obtained from Tocris (Ellisville, MO). Tetrahydrolipstatin (THL) and essentially fatty-acid free bovine serum albumin (BSA) were obtained from Sigma (St Louis, MO). 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and DL-2-amino-5-phosphonovalerate (AP-5) were purchased from Ascent Scientific (Princeton, NJ). All cannabinoids were made up as stock solutions in DMSO; 0.5 g/l BSA was added to artificial cerebral spinal fluid (ACSF) to increase solubility and minimize nonspecific binding of lipophilic compounds. Equal amounts of DMSO and BSA were used in control experiments.
